Immunologic Factor
cantuzumab ravtansine
Definitions related to cantuzumab ravtansine:
-
An immunotoxin of a humanized monoclonal antibody C242 (MoAb HuC242) conjugated to a derivative of the cytotoxic agent maytansine, DM4, with potential antitumor activity. Cantuzumab ravtansine is generated from MoAb C242, which is raised against a cell surface superantigen, CA242, found in a variety of human tumor cells. Upon binding and entry, the immunoconjugate releases the maytansinoid agent DM4, which binds to tubulin, thereby affecting microtubule assembly/disassembly dynamics. As a result, this agent prevents cell division and reduces cell growth of cancer cells that express CA242.NCI ThesaurusU.S. National Cancer Institute, 2021
-
(maytansinoid dm4-conjugated humanized monoclonal antibody huc242) A substance being studied in the treatment of some types of cancer. It is made by linking the monoclonal antibody huC242 to a toxic substance called maytansinoid DM4. The monoclonal antibody binds to the surfaces of cancer cells and the maytansinoid DM4 enters the cells and blocks their growth. It is a type of immunotoxin.NCI Dictionary of Cancer TermsU.S. National Cancer Institute, 2021
Return to OpenMD Medical Dictionary
> C
This content should not be used in place of medically-reviewed decision support reference material or professional medical advice. Some terms may have alternate or updated definitions not reflected in this set. The definitions on this page should not be considered complete or up to date.